ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

New Everolimus Administration Targeting the Prevention of the Development of Antibody-Mediated Rejection Considering the Comparison of Growth and Survival in IgG and IgM Memory B Cells

Y. Matsuda1, R. Imamura1, H. Tezuka2, S. Takahara1

1Osaka University Graduate School of Medicine, Suita, Japan, 2Fujita Health University, Toyoake, Japan

Meeting: 2020 American Transplant Congress

Abstract number: B-106

Keywords: B cells, Immunosuppression, Kidney transplantation

Session Information

Session Name: Poster Session B: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Some reports indicated that immunoglobulin (Ig) M antibodies corresponding to donor-specific antigen in addition to IgG antibodies are closely involved in the activation of humoral immunity against transplanted grafts.Therefore, it is expected that immunosuppression targeting both donor antigen-specific IgG and IgM memory B cell (mBC) survival and growth will play important roles in the prevention of antibody-mediated rejection (AMR) development.

*Methods: mBCs were separated from peripheral blood mononuclear cells obtained from healthy donors (n = 5) via negative selection and incubated with IL-21, IL-4, CpG-ODN, CD40 ligand, PHA-L, and PMA containing AffiniPure F(ab’)2 Fragment Goat Anti-Human IgM, Fc5μ fragment-specific or AffiniPure F(ab’)₂ Fragment Goat Anti-Human IgG, and F(ab’)₂ fragment specific for B cell receptor cross-linking in vitro. We compared the effects of everolimus (EVR; 2.5, 5, and 10 ng/mL) on IgM mBC survival, proliferation, and differentiation into plasma cell and IgG in vitro.Additionally, change in the ratio of IgG-/IgM-positive mBCs during culture and addition time during which IgG/IgM antibody production is more efficiently suppressed were examined.

*Results: EVR inhibited IgM mBC survival, proliferation, and differentiation into IgM-producing plasma cells more strongly compared with IgG in vitro findings.In addition, the ratio of IgG-/IgM-positive cells in mBCs were remarkably increased from day 3 to day 7 of in vitro culture (Fig1-A).EVR (2.5, 5, or 10 ng/ml) addition on day 3 of incubation, as opposed to day 7 or day 10, considerably suppressed both IgG and IgM antibody productions compared with EVR (0 ng/ml) addition (Fig1-B).

*Conclusions: Class switching of IgM in mBCs has been reported to be induced by the reduction of immunosuppression or activation of antigen-antibody reaction in vivo. Therefore, our findings indicate that compared with conventional administration, EVR administration before or immediately after transplantation might prevent AMR development more efficiently.However, differences in the EVR susceptibility for IgM/IgG mBC growth and survival under in vitro and in vivo conditions should be further examined in a larger cohort.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Matsuda Y, Imamura R, Tezuka H, Takahara S. New Everolimus Administration Targeting the Prevention of the Development of Antibody-Mediated Rejection Considering the Comparison of Growth and Survival in IgG and IgM Memory B Cells [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/new-everolimus-administration-targeting-the-prevention-of-the-development-of-antibody-mediated-rejection-considering-the-comparison-of-growth-and-survival-in-igg-and-igm-memory-b-cells/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences